Carlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.
Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).